Shares of Novo Nordisk ended higher on Monday and extended gains in after-hours trading, while "Big Pharma" rival Eli Lilly ...

Administration officials reversed a decision made during the Biden presidency that would have given millions of people access ...

Medicare Advantage updates while halting proposed anti-obesity drug coverage, impacting millions of potential beneficiaries.

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Trump officials reject Medicare coverage ...

President Donald Trump has ordered the Department of Health and Human Services to standardize Medicare payments in an effort ...

A proposal by the Biden administration to cover weight-loss medicines for obesity under Medicare has been axed by the White ...

The proposal would have enabled more Americans to afford new medications in the GLP-1 class that have been shown to reduce ...

Trump administration rejects a Biden plan to expand Medicare coverage of weight-loss drugs such as Zepbound and Wegovy.

The Trump administration has decided not to back a Biden administration plan that would have allowed Medicare to pay for ...

The Trump administration will not permit Medicare to pay for obesity drugs directly ... The decision is a setback for ...

The Trump administration has chosen not to finalize a rule proposed by the Biden administration that would have allowed ...

The U.S. announced an increase in Medicare Advantage payment rates for 2026, exceeding expectations and affecting insurer ...